In a comparison of two medical products stocks, GE HealthCare Technologies (GEHC) emerges as the more attractive value investment option compared to Haemonetics (HAE). GEHC holds a Zacks Rank #2 (Buy) with a Value grade of B, featuring a lower forward P/E ratio of 14.54 and P/B ratio of 2.95. HAE, ranked #3 (Hold) with a Value grade of C, has a higher forward P/E of 19.67 and P/B of 5.64, suggesting GEHC offers better value metrics and a more improving earnings outlook.

The global apheresis market is projected to grow from USD 3.02 billion in 2026 to USD 4.41 billion by 2031, with a CAGR of 7.9%. Growth is driven by rising prevalence of autoimmune and neurological diseases, increased demand for plasma-derived therapies, and technological advances in automated systems. Disposables lead the product segment while plasmapheresis dominates procedures. North America holds the largest regional market share. Key challenges include high procedural costs and limited adoption in emerging markets.

The global therapeutic apheresis market is projected to grow from USD 3.84 billion in 2025 to USD 8.94 billion by 2035, at a CAGR of 7.9%. Growth is driven by increased prevalence of chronic and autoimmune diseases, technological advancements in automated systems, and improved reimbursement policies. Key players include Terumo BCT, Fresenius Kabi, Haemonetics, and B. Braun Melsungen.

Haemonetics Corporation announced the acquisition of Ireland-based Vivasure Medical Limited for €100 million upfront plus up to €85 million in milestone-based payments. The deal adds Vivasure's PerQseal Elite system, a bioabsorbable patch for large-bore vascular access closure, to Haemonetics' interventional portfolio. The technology has received CE Mark approval in Europe and submitted FDA Premarket Approval in the U.S., with strong clinical data showing no major complications.

The Patient Blood Management market is projected to grow from $13.9 billion in 2025 to $23 billion by 2033, driven by AI-enhanced analytics, autologous transfusion technologies, and advancements in blood conservation techniques.

Haemonetics reported Q1 FY2026 financial results with revenue of $321.4 million, missing analyst expectations. Despite revenue decline, the company showed strong organic growth in Plasma and Hospital segments and improved margins.

The global blood bank market is expected to grow significantly from 2025 to 2032, driven by the rising incidence of blood disorders, chronic illnesses, and accidents, as well as advancements in blood bank technologies and increased awareness about blood donation.

The global apheresis equipment market is expected to grow from $4.17 billion in 2023 to $13.17 billion by 2033, at a CAGR of 12.2%. Key drivers include the increasing prevalence of chronic diseases, technological advancements, and growing demand for blood components.

The global blood recovery machine market is expected to grow at a CAGR of 5.9% from 2024 to 2033, driven by advancements in medical technologies, increased awareness of autologous blood transfusion benefits, and rising demand for surgical procedures.

Phibro Animal Health Corporation's robust sales of vaccines and medicated feed additives (MFAs) are driving growth in its Animal Health business. The company's focus on advancing nutritional specialties and vaccine technologies, along with a new vaccine production unit, instills optimism. However, adverse macroeconomic impacts and growing competition from generic alternatives are concerns.

Thermo Fisher Scientific reported better-than-expected Q2 2024 results, with adjusted EPS of $5.37 and revenue of $10.54 billion. The company saw margin expansion but a decline in both reported and organic revenues, particularly in the Life Sciences Solutions and Laboratory Products and Biopharma Services segments.

Elanco Animal Health has divested its aqua business to Merck Animal Health for $1.3 billion, enabling the company to focus on pet health and livestock sustainability while reducing its debt burden.